top banner imagetop banner mobile image

Press Releases

Keyword Search

Date Title
06/10/19
 Summary ToggleTherapeuticsMD to Host Investor and Analyst Day Today
06/07/19
 Summary ToggleTherapeuticsMD and Theramex Enter into Exclusive License and Supply Agreement to Commercialize BIJUVA™ and IMVEXXY® Outside the United States
05/29/19
 Summary ToggleTherapeuticsMD to Host Investor and Analyst Day on June 10, 2019 in New York City
05/08/19
 Summary ToggleTherapeuticsMD Announces Participation at the Bank of America Merrill Lynch 2019 Health Care Conference
05/06/19
 Summary ToggleTherapeuticsMD Announces First Quarter 2019 Financial Results
05/06/19
 Summary ToggleTherapeuticsMD Presented New Research at the American College of Obstetricians and Gynecologists 2019 Annual Meeting that Explores How Women’s Menopausal Symptoms Affect Men
05/03/19
 Summary ToggleTherapeuticsMD Announces Oral and Poster Presentations on BIJUVA™ and ANNOVERA™ at the American College of Obstetricians and Gynecologists 2019 Annual Meeting
04/29/19
 Summary ToggleTherapeuticsMD to Report First Quarter 2019 Results on May 6, 2019
04/24/19
 Summary ToggleTherapeuticsMD Closes $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners
04/17/19
 Summary ToggleTherapeuticsMD Signs Binding Commitment Letter for $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners
04/17/19
 Summary ToggleTherapeuticsMD Announces Commercial Availability of BIJUVA™ in the U.S.
03/25/19
 Summary ToggleTherapeuticsMD Announces Oral and Poster Presentations on BIJUVA™ and ANNOVERA™ at the Endocrine Society 2019 Annual Meeting
03/08/19
 Summary ToggleTherapeuticsMD Announces Oral Presentations on BIJUVA and ANNOVERA, and Poster Presentations Related to Menopause Symptoms and Treatments at 2019 ISSWSH/ISSM Joint Meeting
02/28/19
 Summary ToggleTherapeuticsMD Announces Participation in Two Upcoming Investor Conferences
02/21/19
 Summary ToggleTherapeuticsMD Announces Fourth Quarter and Full-Year 2018 Financial Results
02/08/19
 Summary ToggleTherapeuticsMD to Report Fourth Quarter and Full Year 2018 Results on February 21, 2019
01/03/19
 Summary ToggleTherapeuticsMD Announces Participation at 37th Annual J.P. Morgan Healthcare Conference
11/12/18
 Summary ToggleTherapeuticsMD Announces Participation in Three Upcoming Investor Conferences
11/07/18
 Summary ToggleTherapeuticsMD Announces Third Quarter 2018 Financial Results
10/30/18
 Summary ToggleTherapeuticsMD to Report Third Quarter 2018 Financial Results on November 7, 2018
10/29/18
 Summary ToggleTherapeuticsMD Announces FDA Approval of TX-001HR: BIJUVA™ (Estradiol and Progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause
09/28/18
 Summary ToggleTherapeuticsMD Announces Multiple Presentations Related to Imvexxy™ and TX-001HR at the 2018 Annual Meeting of the North American Menopause Society
09/27/18
 Summary ToggleTherapeuticsMD Enters Into Label Discussions for TX-001HR
09/25/18
 Summary ToggleTherapeuticsMD to Present at 2018 Cantor Global Healthcare Conference
09/20/18
 Summary ToggleTherapeuticsMD Announces the FDA has Granted AnnoveraTM Marketing Exclusivity as a New Chemical Entity
09/13/18
 Summary ToggleTherapeuticsMD Announces Commercial Availability of Imvexxy™ 4 mcg
08/22/18
 Summary ToggleTherapeuticsMD to Present at 13th Annual Wells Fargo Securities Healthcare Conference
08/10/18
 Summary ToggleTherapeuticsMD Announces FDA Approval of ANNOVERA™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control
08/06/18
 Summary ToggleTherapeuticsMD Announces Closing of its Underwritten Public Offering and Concurrent Registered Direct Offering of Common Stock
08/01/18
 Summary ToggleTherapeuticsMD Announces Pricing of Its Underwritten Public Offering and Concurrent Registered Direct Offering for Aggregate Gross Proceeds of $85 Million
07/31/18
 Summary ToggleTherapeuticsMD Licenses Population Council’s Novel Segesterone Acetate/ Ethinyl Estradiol One-Year Vaginal Contraceptive System
07/31/18
 Summary ToggleKnight Therapeutics and TherapeuticsMD Announce Strategic Partnership
07/31/18
 Summary ToggleTherapeuticsMD Announces Proposed $65 Million Underwritten Public Offering and Concurrent $20 Million Registered Direct Offering of Common Stock
07/30/18
 Summary ToggleTherapeuticsMD Announces Second Quarter 2018 Financial Results
07/25/18
 Summary ToggleTherapeuticsMD to Report Second Quarter 2018 Financial Results on July 30, 2018
06/07/18
 Summary ToggleTherapeuticsMD Announces Draw Down of $75 Million Under Term Loan with MidCap Financial
06/07/18
 Summary ToggleTherapeuticsMD to Present at Goldman Sachs 39th Annual Global Healthcare Conference
06/06/18
 Summary ToggleTherapeuticsMD Announces Multiple Presentations at the International Menopause Society’s 16th World Congress
06/04/18
 Summary ToggleTherapeuticsMD to Present at Jefferies 2018 Healthcare Conference
05/31/18
 Summary ToggleTherapeuticsMD Announces Clinical Abstract at the 2018 ASCO Annual Meeting
05/30/18
 Summary ToggleTherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXY™ (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe Dyspareunia, a Symptom of VVA, due to Menopause
05/23/18
 Summary ToggleTherapeuticsMD Comments on Media Reports Regarding TX-004HR
05/16/18
 Summary ToggleTherapeuticsMD Announces Investor and Analyst Day on June 4
05/03/18
 Summary ToggleTherapeuticsMD Announces First Quarter 2018 Financial Results
05/01/18
 Summary ToggleTherapeuticsMD to Host First Quarter Financial Results Conference Call and Webcast on May 3
04/11/18
 Summary ToggleTherapeuticsMD Enters Into Label Negotiations for TX-004HR
04/02/18
 Summary ToggleTherapeuticsMD Announces Expansion of Board of Directors
03/08/18
 Summary ToggleTherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HR
03/06/18
 Summary ToggleTherapeuticsMD to Present at Two Upcoming Investor Conferences
02/20/18
 Summary ToggleTherapeuticsMD Announces Fourth Quarter and Full Year 2017 Financial Results
02/06/18
 Summary ToggleTherapeuticsMD to Host Fourth Quarter and Year End 2017 Financial Results Conference Call and Webcast on February 20
01/03/18
 Summary ToggleTherapeuticsMD Announces Presentation at 36th Annual J.P. Morgan Healthcare Conference on January 10
12/28/17
 Summary ToggleTherapeuticsMD Announces Submission of New Drug Application for TX-001HR
12/19/17
 Summary ToggleTherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for TX-004HR
11/29/17
 Summary ToggleTherapeuticsMD Announces Resubmission of New Drug Application for TX-004HR
11/07/17
 Summary ToggleTherapeuticsMD to Present at Two Upcoming Investor Conferences
11/06/17
 Summary ToggleTherapeuticsMD Announces Third Quarter 2017 Financial Results
11/06/17
 Summary ToggleTherapeuticsMD Announces Plan to Resubmit the New Drug Application for TX-004HR
11/03/17
 Summary ToggleTherapeuticsMD to Host TX-004HR Regulatory Update and Third Quarter Financial Results Conference Call and Webcast on November 6
10/05/17
 Summary ToggleTherapeuticsMD Announces Multiple Presentations Related to TX-004HR and TX-001HR at NAMS 2017
09/28/17
 Summary ToggleTherapeuticsMD Announces Closing of Common Stock Offering
09/25/17
 Summary ToggleTherapeuticsMD Announces Pricing of Common Stock Offering
09/25/17
 Summary ToggleTherapeuticsMD Announces Public Offering of 12.4 Million Shares of Common Stock
09/25/17
 Summary ToggleTherapeuticsMD Announces Move to Nasdaq Global Select Market
09/14/17
 Summary ToggleTherapeuticsMD Announces Submission of Additional Endometrial Safety Information to the New Drug Application for TX-004HR
09/06/17
 Summary ToggleTherapeuticsMD to Present at Two Upcoming Investor Conferences
08/16/17
 Summary ToggleTherapeuticsMD Announces Publication of Manuscript on the Women’s Health Initiative Observational Study of Vaginal Estrogen Use in Postmenopausal Women
08/10/17
 Summary ToggleTherapeuticsMD Provides TX-004HR Regulatory Update
08/03/17
 Summary ToggleTherapeuticsMD Announces Second Quarter 2017 Financial Results
07/20/17
 Summary ToggleTherapeuticsMD to Host Second Quarter Financial Results Conference Call and Webcast on August 3
07/17/17
 Summary ToggleTherapeuticsMD Provides TX-004HR Regulatory Update
05/23/17
 Summary ToggleTherapeuticsMD Announces Presentation at Jefferies 2017 Healthcare Conference on June 8
05/10/17
 Summary ToggleTherapeuticsMD Announces Presentation at Bank of America Merrill Lynch 2017 Healthcare Conference on May 16
05/08/17
 Summary ToggleTherapeuticsMD Receives Complete Response Letter from FDA for TX-004HR New Drug Application
05/02/17
 Summary ToggleTherapeuticsMD to Host TX-004HR Regulatory Update Conference Call and Webcast on May 8
05/02/17
 Summary ToggleTherapeuticsMD Announces First Quarter 2017 Financial Results
04/19/17
 Summary ToggleTherapeuticsMD Provides Additional Information on TX-004HR Regulatory Update
04/10/17
 Summary ToggleTherapeuticsMD Provides TX-004HR Regulatory Update
04/03/17
 Summary ToggleTherapeuticsMD Presents Positive Phase 3 Data in Two Presentations for TX-001HR at ENDO 2017
03/16/17
 Summary ToggleTherapeuticsMD Announces Presentation at the Oppenheimer 27th Annual Healthcare Conference on March 22
03/03/17
 Summary ToggleTherapeuticsMD Announces Presentation at Cowen and Company 37th Annual Healthcare Conference on March 7
02/23/17
 Summary ToggleTherapeuticsMD Announces Fourth Quarter and Full-Year 2016 Financial Results
02/15/17
 Summary ToggleTherapeuticsMD Announces Webcast of Investor Day on March 1
02/09/17
 Summary ToggleTherapeuticsMD to Host Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast on February 23
01/19/17
 Summary ToggleTherapeuticsMD Announces Investor Day on March 1
01/11/17
 Summary ToggleTherapeuticsMD Announces Publication of Two Manuscripts on the Rejoice Trial for TX-004HR in Leading Peer-Reviewed Medical Journal
01/03/17
 Summary ToggleTherapeuticsMD to Present at 35th Annual J.P. Morgan Healthcare Conference on January 11
12/12/16
 Summary ToggleTherapeuticsMD Announces Participation in 2016 BioFlorida Conference
12/05/16
 Summary ToggleTherapeuticsMD Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR
11/08/16
 Summary ToggleTherapeuticsMD to Present at Two Upcoming Investor Conferences
11/03/16
 Summary ToggleTherapeuticsMD Expands Commercial and Business Development Leadership
11/03/16
 Summary ToggleTherapeuticsMD Announces Third Quarter 2016 Financial Results
10/20/16
 Summary ToggleTherapeuticsMD to Host Third Quarter Financial Results Conference Call and Webcast on November 3
09/22/16
 Summary ToggleTherapeuticsMD Announces Multiple Presentations Related to Yuvvexy™ (TX-004HR) at Two Upcoming Medical Conferences
09/19/16
 Summary ToggleTherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for Yuvvexy™ (TX-004HR)
08/04/16
 Summary ToggleTherapeuticsMD Announces Second Quarter 2016 Financial Results
07/20/16
 Summary ToggleTherapeuticsMD to Host Second Quarter Financial Results
07/07/16
 Summary ToggleTherapeuticsMD Announces New Drug Application Submission for Yuvvexy™ (TX-004HR)
06/29/16
 Summary ToggleTherapeuticsMD Announces Filing Timeline for Yuvvexy (TX-004HR) New Drug Application
06/06/16
 Summary ToggleTherapeuticsMD Announces New Innovation in Compliance Packaging for Prenatal Vitamins
06/03/16
 Summary ToggleTherapeuticsMD to Present at Two Upcoming Investor Conferences
05/14/16
 Summary ToggleTherapeuticsMD Presents Poster at ACOG 2016 with Additional Secondary Endpoint Data from Phase 3 Rejoice Trial
05/04/16
 Summary ToggleTherapeuticsMD to Present at Two Upcoming Investor Conferences
05/03/16
 Summary ToggleTherapeuticsMD Announces First Quarter 2016 Financial Results
04/19/16
 Summary ToggleTherapeuticsMD to Host First Quarter 2016 Financial Results Conference Call and Webcast May 3
04/02/16
 Summary ToggleTherapeuticsMD Presents Detailed Results from Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy (VVA) at ENDO 2016
03/02/16
 Summary ToggleTherapeuticsMD to Present Data from Phase 3 Rejoice Trial at Upcoming Investor & Medical Conferences
02/25/16
 Summary ToggleTherapeuticsMD Announces Fourth Quarter and Full Year 2015 Financial Results
02/18/16
 Summary ToggleTherapeuticsMD Announces Poster Presentations at International Society for the Study of Women’s Sexual Health Annual Meeting
02/11/16
 Summary ToggleTherapeuticsMD to Host Fourth Quarter and Year End 2015 Financial Results
01/25/16
 Summary ToggleVitaMedMD Launches VitaTrue™, the First Certified Vegan and Kosher Prescription Prenatal Multivitamin
01/13/16
 Summary ToggleTherapeuticsMD to Present at Noble Financial Capital Markets’ NobleCon12
01/12/16
 Summary ToggleTherapeuticsMD Announces Closing of Common Stock Offering
01/07/16
 Summary ToggleTherapeuticsMD Announces Pricing of $125 Million Common Stock Offering
01/05/16
 Summary ToggleTherapeuticsMD Announces $125 Million Offering of Common Stock
12/07/15
 Summary ToggleTherapeuticsMD Announces Positive Top-Line Results from its Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy (VVA) Treated with 25 mcg, 10 mcg or 4 mcg of TX-004HR
11/11/15
 Summary ToggleTherapeuticsMD to Present at Stifel 2015 Healthcare Conference
11/04/15
 Summary ToggleTherapeuticsMD Announces Third Quarter 2015 Financial Results
10/27/15
 Summary ToggleTherapeuticsMD to Host Third Quarter 2015 Financial Results Conference Call and Webcast November 4
10/13/15
 Summary ToggleTherapeuticsMD Completes Enrollment in Phase 3 Clinical Trial of Bio-identical Oral Combination of Estradiol and Progesterone Product Candidate
09/30/15
 Summary ToggleMenopausal Women Experiencing Distressing Pain During Sex Suffer Due to Misperceptions
09/09/15
 Summary ToggleTherapeuticsMD Announces Presentations at The North American Menopause Society 2015 Annual Meeting
08/06/15
 Summary ToggleTherapeuticsMD Announces Second Quarter 2015 Financial Results
08/05/15
 Summary ToggleTherapeuticsMD receives patent allowance for VVA candidate TX-004HR
07/27/15
 Summary ToggleTherapeuticsMD to Host Second Quarter 2015 Financial Results Conference Call and Webcast August 6
07/09/15
 Summary ToggleTherapeuticsMD Announces Pricing of Common Stock Offering
06/09/15
 Summary ToggleTherapeuticsMD Completes Enrollment in The Rejoice Trial, a Phase 3 Clinical Trial of TX-004HR (estradiol in VagiCap™)
05/26/15
 Summary ToggleTherapeuticsMD, Inc. to participate in upcoming investor conferences
05/21/15
 Summary ToggleTherapeuticsMD, Inc. to participate in upcoming investor conferences
05/06/15
 Summary ToggleTherapeuticsMD Inc. to present at upcoming investor conferences
05/05/15
 Summary ToggleTherapeuticsMD announces first quarter 2015 financial results
05/04/15
 Summary ToggleNew data on compounded prescription practices show differences among medical specialties
04/22/15
 Summary ToggleTherapeuticsMD to host first quarter 2015 financial results conference call and webcast May 5
03/18/15
 Summary ToggleTherapeuticsMD appoints biopharmaceutical senior executives Angus C. Russell and J. Martin Carroll as independent directors
03/10/15
 Summary ToggleTherapeuticsMD announces fourth quarter and full-year 2014 financial results
03/09/15
 Summary TogglePhysicians’ visual assessments correlate with objective measurements of postmenopausal VVA patients treated with TX-004HR VagiCapTM
03/06/15
 Summary TogglePoster: Menopausal Hormone Therapy (MHT) Usage: FDA-Approved MHT Has Decreased While Compounded Non-FDA-Approved MHT Has Increased
03/06/15
 Summary TogglePoster: Vaginal Physical Examination Correlates with Vaginal Epithelial Cells and pH and Can be Used to Assess Treatment Efficacy
02/24/15
 Summary ToggleTherapeuticsMD to host fourth quarter, full-year 2014 financial results conference call and webcast
02/20/15
 Summary ToggleSurvey shows postmenopausal women with VVA reported improved satisfaction and quality of life with VagiCapTM investigational local estrogen treatment
02/11/15
 Summary ToggleTherapeuticsMD announces pricing of common stock offering
02/10/15
 Summary ToggleTherapeuticsMD Announces Offering of Common Stock
12/15/14
 Summary ToggleTherapeuticsMD receives five new patent allowances, further strengthens IP assets
11/20/14
 Summary ToggleTherapeuticsMD ranks No. 1 among Florida companies in Deloitte Technology Fast 500
11/14/14
 Summary ToggleTherapeuticsMD Inc. to present at the Stifel Healthcare Conference
11/06/14
 Summary ToggleTherapeuticsMD announces third quarter financial results
10/23/14
 Summary ToggleTherapeuticsMD to host third quarter 2014 financial results conference call and webcast November 6
10/15/14
 Summary ToggleTherapeuticsMD announces oral presentation of positive phase 2 and bioavailability data on TX-004HR (VagiCapTM)
09/30/14
 Summary ToggleTherapeuticsMD Inc. granted two new patents
09/29/14
 Summary ToggleTherapeuticsMD begins phase 3 clinical trial of TX-004HR
08/06/14
 Summary ToggleTherapeuticsMD announces second quarter 2014 financial results
08/01/14
 Summary ToggleTherapeuticsMD to hold second quarter 2014 financial results conference call and webcast on August 6
07/30/14
 Summary ToggleTherapeuticsMD announces pricing of offering of common stock
07/29/14
 Summary ToggleTherapeuticsMD announces $40 million offering of common stock
06/17/14
 Summary ToggleTherapeuticsMD to present at JMP HealthCare Conference
06/10/14
 Summary ToggleTherapeuticsMD announces 2014 Investor Day webcast on June 16
05/28/14
 Summary ToggleTherapeuticsMD announces release of RediChew and Prena1 Chew
05/22/14
 Summary ToggleTherapeuticsMD to present at Jefferies 2014 HealthCare Conference
05/05/14
 Summary ToggleTherapeuticsMD reports first quarter 2014 results
05/01/14
 Summary ToggleTherapeuticsMD to present the design of its REPLENISH Trial at the IMS 14th World Congress
04/29/14
 Summary ToggleTherapeuticsMD to present at Bank of America Merrill Lynch 2014 Health Care Conference
04/25/14
 Summary ToggleTherapeuticsMD to host conference call and live audio webcast to disclose first quarter financial results
04/07/14
 Summary ToggleTherapeuticsMD reports positive results of rabbit irritation study
04/06/14
 Summary ToggleBocaGreenMD launches PRENA1 PEARL
03/20/14
 Summary ToggleTherapeuticsMD announces pricing of secondary offering
03/19/14
 Summary ToggleVitaMedMD launches vitaPearl
03/18/14
 Summary ToggleTherapeuticsMD announces launch of secondary offering
03/03/14
 Summary ToggleTherapeuticsMD reports fourth quarter and full-year 2013 results
02/25/14
 Summary ToggleTherapeuticsMD to Present at Cowen & Co. 34th Annual Healthcare Conference
02/25/14
 Summary ToggleTherapeuticsMD announces conference call to disclose 2013 year-end results
01/28/14
 Summary ToggleTherapeuticsMD reports positive PK sudy results for its estradiol VagiCap™ (TX-004HR)
01/24/14
 Summary ToggleTherapeuticsMD initiates phase 3 clinical trial of its progesterone candidate (TX-002HR) for treatment of secondary amenorrhea
01/22/14
 Summary ToggleTherapeuticsMD announces issuance of U.S. patent covering TX-001HR
01/06/14
 Summary ToggleTherapeuticsMD announces 50th site for phase 3 clinical trial of TX-001HR
12/18/13
 Summary ToggleTherapeuticsMD names Randall S. Stanicky to Board of Directors
12/09/13
 Summary ToggleTherapeuticsMD receives notice of allowance for patient covering platform technology of oral combination bioidentical 17β-estradiol and progesterone
12/04/13
 Summary ToggleTherapeuticsMD appoints Joel S. Krasnow, M.D. as Chief Scientific Officer
11/22/13
 Summary ToggleTherapeuticsMD to present at 25th annual Piper Jaffray Healthcare Conference
11/19/13
 Summary ToggleTherapeuticsMD applauds congressional leadership on passage of Drug Quality and Security Act
11/04/13
 Summary ToggleTherapeuticsMD reports third quarter 2013 financial results
10/23/13
 Summary ToggleVVA Phase 1 Results
10/23/13
 Summary ToggleTherapeuticsMD appoints Sebastian Mirkin, M.D. as Chief Medical Officer
10/21/13
 Summary ToggleTherapeuticsMD Third Quarter Results Conference Call
10/18/13
 Summary ToggleTherapeuticsMD, Inc. poster wins first-place prize at the North American Menopause Society 2013 Annual Meeting
10/09/13
 Summary TogglePhase 1 data on first oral combination 17β-Estradiol and Progesterone capsule being developed for FDA review
10/04/13
 Summary ToggleTherapeuticsMD to present at 12th Annual BIO Investor Forum
09/25/13
 Summary ToggleTherapeuticsMD announces pricing of offering of common stock
09/05/13
 Summary ToggleTherapeuticsMD begins patient enrollment in pivotal phase 3 clinical trial of TX-001HR
08/29/13
 Summary ToggleTherapeuticsMD to present at STIFEL NICOLAUS 2013 Healthcare Conference
08/12/13
 Summary ToggleTherapeuticsMD Initiates Phase 1 Study Of Estradiol Vagicap™
08/06/13
 Summary ToggleTherapeuticsMD Reports 2nd Quarter 2013 Financial Results
07/01/13
 Summary ToggleTherapeuticsMD, Inc. Added to 2013 Russell Indexes
06/26/13
 Summary ToggleTherapeuticsMD to Present at JMP Securities Healthcare Conference
06/14/13
 Summary ToggleTherapeuticsMD Investigational New Drug Filing Accepted By FDA
06/11/13
 Summary ToggleTherapeuticsMD to Ring Opening Bell at NYSE
05/28/13
 Summary ToggleTherapeuticsMD To Present Jefferies Conference
05/16/13
 Summary ToggleTherapeuticsMD elects Jules A. Musing to Board of Directors
05/08/13
 Summary ToggleTherapeuticsMD reports first quarter 2013 financial results
04/19/13
 Summary ToggleTherapeuticsMD Announces Trading of its Common Stock on the NYSE MKT under symbol "TXMD"
03/15/13
 Summary ToggleTherapeuticsMD Announces Pricing of Public Offering of Common Stock
03/07/13
 Summary ToggleTherapeuticsMD announces $50,000,000 proposed public offering of common stock
11/01/12
 Summary ToggleBocaGreenMD Inc. launches line of generic prescription prenatal multivitamins
09/26/12
 Summary ToggleTherapeuticsMD, Inc. Announces $8.5 Million Private Placement
08/07/12
 Summary ToggleTherapeuticsMD, Inc. Has IND Filing Accepted By FDA
07/17/12
 Summary ToggleTherapeuticsMD, Inc. Launches vitaMedMD™ Iron 21/7, a Unique, Patient-friendly Iron Supplement
07/10/12
 Summary ToggleTherapeuticsMD, Inc. Announces Plans in Hormone Therapy That Concur with the Recent Joint Statement From NAMS, ASRM and the Endocrine Society
06/21/12
 Summary ToggleTherapeuticsMD, Inc. Files for Two Additional Patents on Prescription Products For Treatment of Menopausal Symptoms & Related Conditions
05/16/12
 Summary ToggleTommy G. Thompson, Former U.S. Secretary of Health and Human Services, Joins TherapeuticsMD, Inc. as Chairman
05/10/12
 Summary ToggleTherapeuticsMD, Inc. Launches VitaMedMD RediChew Rx, The First Daily Chewable Prescription Prenatal Vitamin with Quatrefolic
04/09/12
 Summary ToggleTherapeuticsMD, Inc. Launches VitaMedMD One Rx, The First Daily One Pill Prescription Prenatal Vitamin with Quatrefolic and Plant-Based DHA
03/02/12
 Summary ToggleTherapeuticsMD, Inc. Launches VitaMedMD Plus Rx, The First Prescription Prenatal Vitamin with Quatrefolic and Plant-Based DHA
03/02/12
 Summary ToggleTherapeuticsMD, Inc. Elects Four Additional Directors
02/07/12
 Summary ToggleTherapeuticsMD, Inc. Launches Its First Prescription Prenatal Vitamin on March 1, 2012
10/05/11
 Summary ToggleTherapeuticsMD, Inc. Acquires VitaMedMD, LLC